Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-10-03

Clinical Trial Update: Study of a Novel Antipsychotic ITI-007 in Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ITI-007 (lumateperone) in schizophrenia; the study is completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lumateperone (ITI-007) (lumateperone)

Snippet

Sponsor: Intra-Cellular Therapies, Inc. | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2025-10-03